<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777383</url>
  </required_header>
  <id_info>
    <org_study_id>2018-004624-11</org_study_id>
    <nct_id>NCT04777383</nct_id>
  </id_info>
  <brief_title>The Effects of Iontophoresed Vasoactive Drugs on Cutaneus Blood Flow</brief_title>
  <acronym>Jonto01</acronym>
  <official_title>A Non-randomized Experimental Study of Optically Registered Pharmacodynamic Responses During Iontophoresis of Vasoactive Substances to the Skin of Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Linkoeping</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many acute and chronical medical conditions, such as, shock, sepsis, diabetes, hypertonia,&#xD;
      and cardiovascular disease are associated with a perturbated or lost ability of regulating&#xD;
      the diameter of the blood vessels. These changes in regulatory function can be seen&#xD;
      especially in the smaller vessels in the body. It is therefore clinically relevant to develop&#xD;
      investigation models that can detect and quantify such changes at an early stage.&#xD;
&#xD;
      Historically, basic vascular function was investigated by mounting a section of a blood&#xD;
      vessel on a tension sensor, submerging it in a temperature controlled and buffered solution&#xD;
      to which vasoactive substances were added. This in vitro model has contributed substantially&#xD;
      to our current knowledge of vascular pharmacology and function. However, using this method&#xD;
      means that the vessel is removed from its natural environment and, hence no longer influenced&#xD;
      by systemic or local mediators for controlling vessel diameter.&#xD;
&#xD;
      The present study aims to investigate the local changes in blood flow and concentration of&#xD;
      red blood cells of the superficial vessels in the skin of the forearm of healthy volunteers&#xD;
      in response to various vasoactive substances. The purpose is to better understand how the&#xD;
      regulation of diameter works in and to find a model that can give an early warning to when it&#xD;
      does not function optimally.&#xD;
&#xD;
      The vasoactive substances will be delivered through the skin to the vascular bed by a&#xD;
      non-invasive method called iontophoresis. An electrode chamber containing a solution of the&#xD;
      substance to be studied is placed on the subject's skin by double adhesive tape. The chamber&#xD;
      comes with a transparent lid that prevents leakage and enables supervision of the effect on&#xD;
      the underlying vasculature. When a voltage is applied the charged drug molecules begin to&#xD;
      move through the skin and interact with the vessels. In the present study, a total electrical&#xD;
      dose of 12 millicoulomb (mC) is going to be used (600 seconds x 0.02 milliampere).&#xD;
&#xD;
      The effect of the applied drug is measured using two non-contact, optical measurement&#xD;
      techniques.&#xD;
&#xD;
      A better understanding of the pharmacology and regulation of blood vessels may lead to the&#xD;
      developement of techniques that allow earlier detection of perturbations in vessel regulation&#xD;
      and the onset of preventive medical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A non-randomised study to investigate how 6 different vasoactive substances administrated in&#xD;
      5 different concentrations, and with repeated administration affect the cutaneous superficial&#xD;
      vessels. The primary aim is to investigate dose-response mechanisms by use of two&#xD;
      non-invasive optical measurement technologies.&#xD;
&#xD;
      The substances are administrated by iontophoresis using a protocol with a current of 0.02 mA&#xD;
      for 600 seconds, at a total electrical charge of 12 mC. Each drug is diluted using sterile&#xD;
      water into five concentration (1%, 0.1%, 0.01%, 0.001% and 0.0001%). In the sixth chamber&#xD;
      only sterile water will be administrated.&#xD;
&#xD;
      An electrode chamber per concentration is attached to the skin of each subject's forearm and&#xD;
      each concentration is administrated three times.&#xD;
&#xD;
      Only one substance at a time will be administrated.&#xD;
&#xD;
      The substances used are:&#xD;
&#xD;
        -  Acetylcholine - vasodilator (Miochol-E, 10mg/ml, Bausch and Lomb)&#xD;
&#xD;
        -  Noradrenaline - vasoconstrictor (Noradrenaline, 10mg/ml, Pfizer)&#xD;
&#xD;
        -  Phenylephrine - vasoconstrictor (Phenylephrine, 10mg/ml, Unimedic)&#xD;
&#xD;
        -  Atropine - anticholinergic (Atropine, 10mg/ml, Bausch and Lomb)&#xD;
&#xD;
        -  Neostigmine - acetylcholineesterase inhibitor (Neostigmine, 10mg/ml, Unimedic Pharma)&#xD;
&#xD;
        -  Dilutor: sterile water (Sterile water, 100 ml, Braun)&#xD;
&#xD;
      Iontophoresis protocol: 0.02 mA x 600 seconds x 3 repetitions per drug concentration and&#xD;
      localization. Each iontophoretic pulse is preceded by a baseline registration and followed by&#xD;
      a 30 minutes wash-out/recovery period.&#xD;
&#xD;
      Vascular effects are continuously, non-invasively and indirectly measured using tissue&#xD;
      viability imaging (TiVi, cross-polarized diffuse reflectance spectroscopy) and multi-exposure&#xD;
      laser speckle contrast imaging (MELSCI). The optical measurement modalities are placed at a&#xD;
      distance of approximately 30 cm above the skin surface so that the vascular responses can be&#xD;
      measured in three electrode chambers simultaneously for the duration of the test (120&#xD;
      minutes).&#xD;
&#xD;
      TiVi settings - 1 image/minute at 6000 x 4000 pixels MELSCI settings - 15.6 frames/second at&#xD;
      1024 x 1000 pixels&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Iontophoresis of vasoactive substances in 5 different concentrations. Each concentration is administrated 3 times to the same localisation.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locally induced changes in red blood cell concentration and movement due to iontophoresis of vasoactive substances.</measure>
    <time_frame>Measured prior the onset of iontophoresis (baseline), then continuously for the duration of the iontophoretic pulse (10 minutes) and for the 30 minute wash-out period following each iontophoretic pulse.</time_frame>
    <description>Optically derived arbitrary values that correlate to the concentration and movement of red blood cells in the vessels.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iontophoretically administered vasoactive substances in five concentrations (1%,0.1%,0.01%,0.001%, 0.0001%) dissolved in sterile water. Each concentration of the drug is separately administered using a electrical charge of 12 millicoulomb (mC) (600 seconds x 0.02 milliampere) for 3 repeated pulses (total electrical charge 36 mC). Each iontophoresis pulse is separated by a 30 minute wash-out period.&#xD;
Vasoactive substances:&#xD;
Miochol-E (Acetylcholine),10 mg/ml, Bausch &amp; Lomb&#xD;
Methacholine chloride, 100 mg/ml, APL&#xD;
Norepinephrine, 1 mg/ml, Pfizer&#xD;
Phenylephrine, 10 mg/ml, Unimedic&#xD;
Atropine, 10 mg/ml, Bausch &amp; Lomb&#xD;
Neostigmine, 2.5 mg/ml, Unimedic Pharma&#xD;
Sterile water, 100 ml, Braun</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylcholine</intervention_name>
    <description>Iontophoretic administration of 5 different concentrations of acetylcholine</description>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <other_name>Miochol-E, 10mg/ml, Bausch and Lomb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>Iontophoretic administration of 5 different concentrations of norepinephrine</description>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <other_name>Norepinephrine, 1 mg/ml, Pfizer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenylephrine</intervention_name>
    <description>Iontophoretic administration of 5 different concentrations of phenylephrine</description>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <other_name>Phenylephrine, 10 mg/ml, Unimedic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine</intervention_name>
    <description>Iontophoretic administration of 5 different concentrations of atropine</description>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <other_name>Atropine, 10 mg/ml, Bausch &amp; Lomb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Iontophoretic administration of 5 different concentrations of neostigmine</description>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <other_name>Neostigmine, 2.5 mg/ml, Unimedic Pharma</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sterile water</intervention_name>
    <description>Iontophoretic administration of sterile water</description>
    <arm_group_label>Vascular effects of iontophoresed vasoactive substances</arm_group_label>
    <other_name>Sterile water, 100 ml, Braun</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  No ongoing medication&#xD;
&#xD;
          -  No skin disease or other skin afflictions&#xD;
&#xD;
          -  Informed, voluntary participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing medication (contraceptives excluded)&#xD;
&#xD;
          -  Hypertonia, skin disease or skin afflictions, cardiovascular disease, pregnancy&#xD;
&#xD;
          -  Damaged skin, bruises, scar tissue or tattoos on the skin of the forearms&#xD;
&#xD;
          -  Smoking (6 months prior to study onset, or more than 100 cigarettes in life)&#xD;
&#xD;
          -  Snus (6 months prior to study onset)&#xD;
&#xD;
          -  Use of nicotine products (gum, patch, et cetera) 6 months prior to study onset&#xD;
&#xD;
          -  Blood pressure above 140/90&#xD;
&#xD;
          -  Coffee, tea, alcohol or strenuous physical activity on the day of the study&#xD;
&#xD;
          -  Not fasting for 2 hours prior onset of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Wilhelms, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linkoeping University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Wilhelms, Phd</last_name>
    <phone>+46(0)101030000</phone>
    <email>daniel.wilhelms@liu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joakim Henricson, Phd</last_name>
    <phone>+46(0)722346224</phone>
    <email>joakim.henricson@regionostergotland.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Linköping</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Wilhelms, PhD</last_name>
      <phone>+461030000</phone>
      <email>daniel.wilhelms@liu.se</email>
    </contact>
    <contact_backup>
      <last_name>Joakim Henricson, PhD</last_name>
      <phone>+461030000</phone>
      <email>joakim.henricson@regionostergotland.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Linkoeping</investigator_affiliation>
    <investigator_full_name>Daniel Wilhelms</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>iontophoresis</keyword>
  <keyword>pharmacology</keyword>
  <keyword>tissue viability imaging</keyword>
  <keyword>multi-exposure laser speckle contrast imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Acetylcholine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

